Clinical Trials
Biogen Initiates Phase 3 Trial for Felzartamab in Kidney Transplant Rejection
Drugs.com
•
March 11, 2025
Biogen announced the initiation of a global Phase 3 clinical trial evaluating felzartamab for the treatment of late antibody-mediated rejection (AMR) in kidney transplant patients. This addresses a significant unmet need in transplant medicine.
Biogen's initiation of a Phase 3 trial for felzartamab represents a crucial step in addressing late antibody-mediated rejection (AMR) following kidney transplants. AMR is a major cause of graft loss and poses a significant challenge in transplant care. The development of felzartamab as a potential treatment offers hope for improving long-term outcomes for transplant recipients. The initiation of a Phase 3 trial signifies confidence in the drug's potential efficacy and safety based on earlier clinical data. Positive results from this trial could lead to a new treatment option for a condition with significant unmet medical needs.